Trials / Completed
CompletedNCT00565370
Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
A Phase I-II Study of Sorafenib (Nexavar®) in Combination With Capecitabine and Cisplatin (XP) in Patients With Advanced Gastric Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
There is strong scientific rationale for exploring the role of sorafenib with capecitabine and cisplatin (XP) in AGC. XP is a new standard of care in AGC and sorafenib is a novel signal transduction inhibitor that prevents tumor cell proliferation and angiogenesis through blockade of the Raf/MEK/ERK pathway at the level of Raf kinase and the receptor tyrosine kinases VEGF-R2 and PDGFR-beta.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine, Cisplatin, Sorafenib | Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2007-11-29
- Last updated
- 2020-01-18
- Results posted
- 2015-08-31
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00565370. Inclusion in this directory is not an endorsement.